Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
2014.
New FDA Breakthrough-Drug Category — Implications for Patients.
New England Journal of Medicine,
Vol. 371,
Issue. 1,
p.
87.
Rex, John H.
Goldberger, Mark
Eisenstein, Barry I.
and
Harney, Carrie
2014.
The evolution of the regulatory framework for antibacterial agents.
Annals of the New York Academy of Sciences,
Vol. 1323,
Issue. 1,
p.
11.
So, Anthony D.
and
Shah, Tejen A.
2014.
New business models for antibiotic innovation.
Upsala Journal of Medical Sciences,
Vol. 119,
Issue. 2,
p.
176.
Mullard, Asher
2014.
Momentum builds around new antibiotic business models.
Nature Reviews Drug Discovery,
Vol. 13,
Issue. 10,
p.
711.
Collyar, Deborah E.
2014.
Collaborative Innovation in Drug Discovery.
p.
663.
Laxminarayan, Ramanan
2014.
Antibiotic effectiveness: Balancing conservation against innovation.
Science,
Vol. 345,
Issue. 6202,
p.
1299.
Kinch, Michael S.
and
Flath, Richard
2015.
New drug discovery: extraordinary opportunities in an uncertain time.
Drug Discovery Today,
Vol. 20,
Issue. 11,
p.
1288.
Giri, Shibashish
and
Bader, Augustinus
2015.
A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells.
Drug Discovery Today,
Vol. 20,
Issue. 1,
p.
37.
Outterson, Kevin
Powers, John H.
Daniel, Gregory W.
and
McClellan, Mark B.
2015.
Repairing The Broken Market For Antibiotic Innovation.
Health Affairs,
Vol. 34,
Issue. 2,
p.
277.
Hwang, Thomas J
Powers, John H
Carpenter, Daniel
and
Kesselheim, Aaron S
2015.
Accelerating innovation in rapid diagnostics and targeted antibacterials.
Nature Biotechnology,
Vol. 33,
Issue. 6,
p.
589.
Kinch, Michael S.
Hoyer, Denton
Patridge, Eric
and
Plummer, Mark
2015.
Target selection for FDA-approved medicines.
Drug Discovery Today,
Vol. 20,
Issue. 7,
p.
784.
Kinch, Michael S.
2015.
Post-approval fate of pharmaceutical companies.
Drug Discovery Today,
Vol. 20,
Issue. 2,
p.
170.
Capati, Vincent C.
and
Kesselheim, Aaron S.
2016.
Drug Product Life-Cycle Management as Anticompetitive Behavior: The Case of Memantine.
Journal of Managed Care & Specialty Pharmacy,
Vol. 22,
Issue. 4,
p.
339.
Rex, John
and
Outterson, Kevin
2016.
Antibiotic Reimbursement in a Model Delinked from Sales: A Benchmark-Based Worldwide Approach.
SSRN Electronic Journal ,
Rex, John H
and
Outterson, Kevin
2016.
Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
The Lancet Infectious Diseases,
Vol. 16,
Issue. 4,
p.
500.
Deak, Dalia
Outterson, Kevin
Powers, John H.
and
Kesselheim, Aaron S.
2016.
Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration–Approved Antibiotics, 2010–2015.
Annals of Internal Medicine,
Vol. 165,
Issue. 5,
p.
363.
Maxson, Tucker
and
Mitchell, Douglas A.
2016.
Targeted treatment for bacterial infections: prospects for pathogen-specific antibiotics coupled with rapid diagnostics.
Tetrahedron,
Vol. 72,
Issue. 25,
p.
3609.
Parsonage, Ben
Hagglund, Philip K.
Keogh, Lloyd
Wheelhouse, Nick
Brown, Richard E.
and
Dancer, Stephanie J.
2017.
Control of Antimicrobial Resistance Requires an Ethical Approach.
Frontiers in Microbiology,
Vol. 8,
Issue. ,
Hey, Spencer Phillips
and
Kesselheim, Aaron S.
2017.
Reprioritizing Research Activity for the Post‐Antibiotic Era:Ethical, Legal, and Social Considerations.
Hastings Center Report,
Vol. 47,
Issue. 2,
p.
16.
Cope, Anwen L
and
Lewis, Michael AO
2017.
Antibiotic guardians: the role of the dental profession.
Dental Update,
Vol. 44,
Issue. 4,
p.
275.